CI Investments Inc. Buys 3,109 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• CI Investments raised its stake in Alnylam by 75.6% in Q3, adding 3,109 shares to own 7,224 shares valued at about $3.29 million per its Form 13F filing.
• Significant insider selling has occurred recently — CEO Yvonne Greenstreet and multiple EVPs sold shares, with insiders offloading 53,923 shares worth ~$18.07 million over the last 90 days while insiders now own just 1.5% of the stock.
• Alnylam missed quarterly estimates (EPS $1.25 vs. $1.43 expected; revenue $1.10B vs. $1.16B) despite revenue rising 84.9% year-over-year, and analysts maintain a "Moderate Buy" consensus with an average target of ~$477.96.

CI Investments Inc. lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,224 shares of the biopharmaceutical company's stock after acquiring an additional 3,109 shares during the period. CI Investments Inc.'s holdings in Alnylam Pharmaceuticals were worth $3,294,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Focus Partners Advisor Solutions LLC boosted its stake in Alnylam Pharmaceuticals by 533.0% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 5,127 shares of the biopharmaceutical company's stock worth $2,282,000 after purchasing an additional 4,317 shares during the period. Elo Mutual Pension Insurance Co boosted its position in shares of Alnylam Pharmaceuticals by 26.5% during the third quarter. Elo Mutual Pension Insurance Co now owns 17,865 shares of the biopharmaceutical company's stock worth $8,146,000 after buying an additional 3,738 shares during the period. Quantbot Technologies LP acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $536,000. Aster Capital Management DIFC Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $36,000. Finally, Andra AP fonden raised its position in Alnylam Pharmaceuticals by 200.0% in the 3rd quarter. Andra AP fonden now owns 20,700 shares of the biopharmaceutical company's stock valued at $9,439,000 after buying an additional 13,800 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Neutral Sentiment: Short-interest reads are unreliable — filings report a “large increase” but show 0 shares and NaN changes, with days-to-cover of 0.0; this appears to be a data error and is unlikely to be driving meaningful buying or selling pressure.
• Neutral Sentiment: Protego Biopharma appointed John M. Maraganore, Ph.D., to its board. Maraganore is a former Alnylam CEO; the move is an external board appointment and is unlikely to materially affect Alnylam’s fundamentals. Protego Biopharma Appoints John M. Maraganore
• Negative Sentiment: Insider sales by senior management: multiple executives sold shares in early March — CEO Yvonne Greenstreet sold 6,799 shares (~$2.23M) reducing her holding by 6.45%; several EVPs (Tolga Tanguler, Kevin J. Fitzgerald, Pushkal Garg, Jeffrey V. Poulton) also sold blocks (each mid-five-figure shares, roughly $0.5M–$0.72M per filing), trimming their positions by ~3–7%. These clustered insider sales can be perceived negatively by the market even if they are routine diversification. SEC filings: Greenstreet SEC filing Tanguler SEC filing Fitzgerald SEC filing Garg SEC filing Poulton SEC filing

Alnylam Pharmaceuticals Stock Up 2.7%

Alnylam Pharmaceuticals stock opened at $327.30 on Thursday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The company's 50-day moving average is $355.63 and its 200-day moving average is $416.41. The firm has a market capitalization of $43.41 billion, a PE ratio of 191.40 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company's revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.65) EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the subject of a number of recent research reports. Royal Bank Of Canada reduced their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an "outperform" rating for the company in a research report on Tuesday, January 20th. Bank of America restated a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Chardan Capital decreased their target price on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a "buy" rating for the company in a research report on Friday, February 13th. Leerink Partners cut their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a "market perform" rating on the stock in a research report on Monday, December 15th. Finally, Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating for the company in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $477.96.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares of the company's stock, valued at $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Pushkal Garg sold 2,242 shares of the company's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president owned 24,848 shares in the company, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last 90 days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.